Palantir Technologies, SL Green Realty And A Healthcare Stock On CNBC's 'Final Trades'
Portfolio Pulse from Avi Kapoor
SL Green Realty, Palantir Technologies, and DexCom were featured on CNBC's 'Final Trades'. SL Green Realty reported weaker-than-expected Q4 results. Palantir was awarded a $178.4 million Army contract for the TITAN ground station system. DexCom's Stelo Glucose Biosensor System received FDA approval as the first OTC continuous glucose monitor. Shares of SLG, PLTR, and DXCM saw gains in their recent trading sessions.
March 07, 2024 | 1:51 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
DexCom's Stelo Glucose Biosensor System received FDA approval, shares climbed 9.8%.
The FDA approval of DexCom's Stelo Glucose Biosensor System as the first OTC continuous glucose monitor and the 9.8% rise in shares reflect the market's positive reception to this significant regulatory milestone.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 90
POSITIVE IMPACT
Palantir was awarded a $178.4 million Army contract for the TITAN system, shares rose 9.9%.
The significant Army contract win for Palantir and the subsequent 9.9% increase in share price indicate strong investor confidence in the company's commercial business and future growth prospects.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 90
POSITIVE IMPACT
SL Green Realty reported weaker-than-expected Q4 results but shares gained 2% recently.
Despite the weaker-than-expected Q4 results, the increase in SLG's share price suggests investors might be focusing on future potential or other positive aspects not detailed in the news.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 80